Advertisement

MASCC recommendations on the management of constipation in patients with advanced cancer

  • Andrew DaviesEmail author
  • Charlotte Leach
  • Ricardo Caponero
  • Andrew Dickman
  • David Fuchs
  • Judith Paice
  • Anton Emmanuel
Review Article

Abstract

Purpose

The Palliative Care Study Group of the Multinational Association for Supportive Care in Cancer formed a subgroup to develop evidence-based recommendations on the management of constipation in patients with advanced cancer.

Methods

These recommendations were developed in accordance with the MASCC Guidelines Policy. A search strategy for Medline was developed, and the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials were explored for relevant reviews/trials respectively. The recommendations were categorised by the level of evidence and a “category of guideline” based on the level of evidence (i.e. “recommendation”, “suggestion”, or “no guideline possible”).

Results

The group produced 15 recommendations, with varying levels of evidence and so varying categories of guideline. The recommendations relate to the assessment, the treatment, and the re-assessment of constipation.

Conclusions

These recommendations provide a framework for the management of constipation in advanced cancer, although every patient needs individualised management.

Keywords

Constipation Neoplasms Palliative care Practice guideline 

Notes

Compliance with ethical standards

Conflict of interest

ADavies has received personal fees and research funding from Kyowa Kirin; CL has received personal fees from Kyowa Kirin; ADickman has received personal fees from Kyowa Kirin; DF has received personal fees from Novartis, Pfizer, and Roche.

References

  1. 1.
    Laugsand EA, Jakobsen G, Kaasa S, Klepstad P (2011) Inadequate symptom control in advanced cancer patients across Europe. Support Care Cancer 19:2005–2014CrossRefGoogle Scholar
  2. 2.
    Noguera A, Centeno C, Librada S, Nabal M (2010) Clinical use of oral laxatives in palliative care services in Spain. Support Care Cancer 18:1491–1494CrossRefGoogle Scholar
  3. 3.
    Sera L, McPherson ML (2018) Management of opioid-induced constipation in hospice patients. Am J Hosp Palliat Med 35:330–335CrossRefGoogle Scholar
  4. 4.
    Larkin PJ, Cherny NI, La Carpia D, Guglielmo M, Ostgathe C, Scotte F et al (2018) Daignosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol 29(Suppl 4):iv94–iv108Google Scholar
  5. 5.
    Anonymous (2010) Oxford concise medical dictionary, 8th edn. Oxford University Press, OxfordGoogle Scholar
  6. 6.
    Lindberg G, Hamid SS, Malfertheiner P, Thomsen OO, Fernandez LB, Garisch J et al (2011) World gastroenterology organisation global guideline: constipation: a global perspective. J Clin Gastroenterol 45:483–487CrossRefGoogle Scholar
  7. 7.
    Walter S, Hallbook O, Gotthard R, Bergmark M, Sjodahl R (2002) A population-based study on bowel habits in a Swedish community: prevalence of faecal incontinence and constipation. Scand J Gastroenterol 37:911–916CrossRefGoogle Scholar
  8. 8.
    Lee TH, Choi SC, Park MI, Park KS, Shin JE, Kim SE, Jung KW, Koo HS, Kim WJ, Cho YK, Kim YS, Lee JS, (2014) Constipation misperception is associated with gender, marital status, treatment utilization and constipation symptoms experienced. J Neurogastroenterol Motil 20:379–387Google Scholar
  9. 9.
    Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R (2016) Bowel disorders. Gastroenterology 150:1393–1407CrossRefGoogle Scholar
  10. 10.
    Farmer AD, Drewes AM, Chiarioni G, De Giorgio R, O’Brien T, Morlion B et al (2018) Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United European Gastroenterol JGoogle Scholar
  11. 11.
    Laugsand EA, Skorpen F, Kaasa S, Sabatowski R, Strasser F, Fayers P, Klepstad P (2015) Genetic and non-genetic factors associated with constipation in cancer patients receiving opioids. Clin Transl Gastroenterol 6:e90CrossRefGoogle Scholar
  12. 12.
    Hadley G, Derry S, Moore RA, Wiffen PJ (2013) Transdermal fentnayl for cancer pain. Cochrane Database of Systematic Reviews Issue 10. Art. No.: CD010270Google Scholar
  13. 13.
    Fallon MT, Hanks GW (1999) Morphine, constipation and performance status in advanced cancer patients. Palliat Med 13:159–160CrossRefGoogle Scholar
  14. 14.
    Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM (2014) Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil 26:1386–1395CrossRefGoogle Scholar
  15. 15.
    Suares NC, Ford AC (2011) Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 106:1582–1591CrossRefGoogle Scholar
  16. 16.
    Larkin PJ, Sykes NP, Centeno C, Ellershaw JE, Elsner F, Eugene B, Gootjes JRG, Nabal M, Noguera A, Ripamonti C, Zucco F, Zuurmond WWA, On behalf of The European Consensus Group on Constipation in Palliative Care (2008) The management of constipation in palliative care: clinical practice recommendations. Palliat Med 22:796–807CrossRefGoogle Scholar
  17. 17.
    Oosten AW, Oldenmenger WH, Mathijssen RH, van der Rijt CC (2015) A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J Pain 16:935–946CrossRefGoogle Scholar
  18. 18.
    Johanson JF, Kralstein J (2007) Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 25:599–608CrossRefGoogle Scholar
  19. 19.
    Davies A, Webber K (2015) Stercoral perforation of the colon: a potentially fatal complication of opioid-induced constipation. J Pain Symptom Manag 50:260–262CrossRefGoogle Scholar
  20. 20.
    Yamada N, Nakamura M, Ishikura K, Ota M, Yazu T, Ota S, Ito M, Fujioka H, Isaka N, Nakano T (2005) Triggers of acute pulmonary thromboembolism devleoped in hospital, with focusing on toliet activities as triggering acts. Int J Cardiol 98:409–411CrossRefGoogle Scholar
  21. 21.
    Dhingra L, Shuk E, Grossman B, Strada A, Wald E, Portenoy A, Knotkova H, Portenoy R (2013) A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med 27:447–456CrossRefGoogle Scholar
  22. 22.
    Friedrichsen M, Erichsen E (2004) The lived experience of constipation in cancer patients in palliative hospital-based home care. Int J Palliat Nurs 10:321–325CrossRefGoogle Scholar
  23. 23.
    Hjalte F, Berggren A-C, Bergendahl H, Hjortsberg C (2010) The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manag 40:696–703CrossRefGoogle Scholar
  24. 24.
    Hess B, Bernardi M, Klotz H-P (2011) Attitude of Swiss physicians towards opioid-induced constipation: a national survey. Eur J Intern Med 22:527–531CrossRefGoogle Scholar
  25. 25.
    Multinational Association for Supportive Care in Cancer Guidelines Policy: https://www.mascc.org/assets/Toolbox/PoliciesForms/mascc_guideline_policy_2018.pdf Accessed 4th November 2018
  26. 26.
    National Cancer Institute Dictionary of Cancer https://www.cancer.gov/publications/dictionaries/cancer-terms Accessed 4th November 2018
  27. 27.
    Cochrane Database of Systematic Reviews: https://www.cochranelibrary.com/cdsr/about-cdsr Accessed 4th November 2018
  28. 28.
    Cochrane Central Register of Controlled Trials (CENTRAL): https://www.cochranelibrary.com/central/about-central Accessed 4th November 2018
  29. 29.
    National Institute for Health and Care Excellence (2015) Naloxegol for treating opioid-induced constipation. Technology Appraisal Guidance [TA345]. NICE, LondonGoogle Scholar
  30. 30.
    Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32:920–924CrossRefGoogle Scholar
  31. 31.
    Clark K, Currow DC, Talley NJ (2010) The use of digital rectal examinations in palliative care patients. J Palliat Med 13:797CrossRefGoogle Scholar
  32. 32.
    Palsson OS, Whitehead WE, van Tilburg MA, Chang L, Chey W, Crowell MD et al (2016) Development and validation of the Rome IV Diagnostic Questionnaire for adults. Gastroenterology 150:1481–1491CrossRefGoogle Scholar
  33. 33.
    Starreveld JS, Pols MA, Van Wijk HJ, Bogaard JW, Poen H, Smout AJ (1990) The plain abdominal radiograph in the assessment of constipation. Z Gastroenterol 28:335–338Google Scholar
  34. 34.
    Nagaviroj K, Yong WC, Fassbender K, Zhu G, Oneschuk D (2011) Comparison of the constipation assessment scale and plain abdominal radiography in the assessment of constipation in advanced cancer patients. J Pain Symptom Manag 42:222–228CrossRefGoogle Scholar
  35. 35.
    Dzierzanowski T, Cialkowska-Rysz A (2015) Behavioral risk factors of constipation in palliative care patients. Support Care Cancer 23:1787–1793CrossRefGoogle Scholar
  36. 36.
    Emmanuel A (2011) Current management strategies and therapeutic targets in chronic constipation. Ther Adv Gastroenterol 4:37–48CrossRefGoogle Scholar
  37. 37.
    Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V, for the Expert Working Group of the European Association of Palliative Care Network (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542–2554CrossRefGoogle Scholar
  38. 38.
    Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P (2015) Laxatives for the management of constipation in people receiving palliative care. Cochrane Database of Systematic Reviews Issue 5. Art. No.: CD003448Google Scholar
  39. 39.
    Brandt LJ, Prather CM, Quigley EM, Schiller LR, Shoenfeld P, Talley NJ (2005) Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 100:S5–S22CrossRefGoogle Scholar
  40. 40.
    Lee-Robichaud H, Thomas K, Morgan J, Nelson RL (2010) Lactulose vesrus polyethylene glycol for chronic constipation. Cochrane Database of Systematic Reviews Issue 7. Art. No.: CD007570Google Scholar
  41. 41.
    American Gastroenterological Association (2013) American Gastroenterological Association medical position statement on constipation. Gastroenerology 144:211–217CrossRefGoogle Scholar
  42. 42.
    Librach SL, Bouvette M, De Angelis C, Farley J, Oneschuk D, Pereira JL et al (2010) Consensus recommendations for the management of constipation in patients with advanced, progressive illness. J Pain Symptom Manag 40:761–773CrossRefGoogle Scholar
  43. 43.
    British Medical Association and the Royal Pharmaceutical Society (2017) British National Formulary 74. Pharmaceutical Press, BasingstokeGoogle Scholar
  44. 44.
    Ford AC, Suares NC (2011) Effect of laxatives and pharmacological therpaies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 60:209–218CrossRefGoogle Scholar
  45. 45.
    Thomas J, Karyer S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE et al (2008) Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358: 2332-2343. Send toGoogle Scholar
  46. 46.
    Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ (2017) Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Pract 17:820–828CrossRefGoogle Scholar
  47. 47.
    Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J (2014) Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 370:2387–2396CrossRefGoogle Scholar
  48. 48.
    Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, Arai M, Tada Y, Narabayashi M, Boku N (2017) Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer. J Clin Oncol 35:3859–3866CrossRefGoogle Scholar
  49. 49.
    Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P (2018) Mu-opioid anatagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. Cochrane Database of Systematic Reviews Issue 6. Art. No.: CD006332Google Scholar
  50. 50.
    Nee J, Zakari M, Sugarman MA, Whelan J, Hirsch W, Sultan S, Ballou S, Iturrino J, Lembo A (2018) Efficacy of treatments for opioid-induced constipation: systematic review and meta-anlysis. Clin Gastroenterol Hepatol 16:1569–1584CrossRefGoogle Scholar
  51. 51.
    Sykes NP (1996) An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 10:135–144CrossRefGoogle Scholar
  52. 52.
    Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M (2017) A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR. Eur J Pain 21:1528–1537CrossRefGoogle Scholar
  53. 53.
    Clark K, Byfieldt N, Dawe M, Currow DC (2012) Treating constipation in palliative care: the impact of other factors aside from opioids. Am J Hosp Palliat Care 29:122–125CrossRefGoogle Scholar
  54. 54.
    Cryer B, Katz S, Vallejo R, Popescu A, Ueno R (2014) A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 15:1825–1834CrossRefGoogle Scholar
  55. 55.
    Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M (2010) Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced costipation. Dig Dis Sci 55:2912–2921CrossRefGoogle Scholar
  56. 56.
    Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, de Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68CrossRefGoogle Scholar
  57. 57.
    National Comprehensive Cancer Network (2018) Adult cancer pain version 1.2018. National Comprehensive Cancer Network, Plymouth MeetingGoogle Scholar
  58. 58.
    Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, Oishi R, Sendo T, Araki H, Itoh Y (2012) A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain 28:373–381CrossRefGoogle Scholar
  59. 59.
    Wilkinson-Smith V, Bharucha AE, Emmanuel A, Knowles C, Yiannakou Y, Corsetti M (2018) When all else seems lost: management of refractory constipation - surgery, rectal irrigation, percutaneous endoscopic colostomy, and more. Neurogastroenterol Motil 30:e13352CrossRefGoogle Scholar
  60. 60.
    Lau CH, Wu X, Chung VC, Liu X, Hui EP, Cramer H et al (2016) Acupuncture and related therapies for symptom management in palliative cancer care: systematic review and meta-analysis. Medicine (Baltimore) 95:e2901CrossRefGoogle Scholar
  61. 61.
    Lai TK, Cheung MC, Lo CK, Ng KL, Fung YH, Tong M et al (2011) Effectiveness of aroma massage on advanced cancer patients with constipation: a pilot study. Complement Ther Clin Pract 17:37–43CrossRefGoogle Scholar
  62. 62.
    Tavares CN, Kimbrel JM, Protus BM, Grauer PA (2014) Petroleum jelly (vaseline balls) for the treatment of constipation: a survey of hospice and palliative care practitioners. Am J Hosp Palliat Care 31:797–803CrossRefGoogle Scholar
  63. 63.
    Mercadante S, Ferrera P, Casuccio A (2011) Effectiveness and tolerability of amidotrizoate for the treatment of constipation resistant to laxatives in advanced cancer patients. J Pain Symptom Manag 41:421–425CrossRefGoogle Scholar
  64. 64.
    Rubiales AS, Hernansanz S, Gutierrez C, Del Valle ML, Flores LA (2006) Neostigmine for refractory constipation in advanced cancer patients. J Pain Symptom Manag 32:204–205CrossRefGoogle Scholar
  65. 65.
    Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, Galluzzi KE, Gudin J, Lembo A, Stanos SP, Webster LR (2015) Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med 16:2324–2337CrossRefGoogle Scholar
  66. 66.
    Rentz AM, Yu R, Muller-Lissner S, Leyendecker P (2009) Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 12:371–383CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Royal Surrey County HospitalGuildfordUK
  2. 2.Hospital Alemão Oswaldo CruzSão PauloBrazil
  3. 3.Royal Liverpool HospitalLiverpoolUK
  4. 4.Kepler University HospitalLinzAustria
  5. 5.Northwestern UniversityChicagoUSA
  6. 6.University College London HospitalsLondonUK

Personalised recommendations